Molecular bacterial load assay versus culture for monitoring treatment response in adults with tuberculosis
- PMID: 34349999
- PMCID: PMC8287413
- DOI: 10.1177/20503121211033470
Molecular bacterial load assay versus culture for monitoring treatment response in adults with tuberculosis
Abstract
The lack of rapid, sensitive, and deployable tuberculosis diagnostic tools is hampering the early diagnosis of tuberculosis and early detection of treatment failures. The conventional sputum smear microscopy or Xpert MTB/RIF assay cannot distinguish between alive and dead bacilli and the culture method delays providing results. Tuberculosis molecular bacterial load assay is a reverse transcriptase real-time quantitative polymerase chain reaction that quantifies viable tuberculosis bacillary load as a marker of treatment response for patients on anti-tuberculosis therapy. However, results are not synthesized enough to inform its comparative advantage to tuberculosis culture technique which is yet the gold standard of care. With this review, we searched electronic databases, including PubMed, Embase, and Web of Science, from March 2011 up to February 2021 for clinical trials or prospective cohort studies that compared tuberculosis molecular bacterial load assay with tuberculosis culture in adults. We included eight studies that meet the inclusion criteria. Tuberculosis molecular bacterial load assay surpasses culture in monitoring patients with tuberculosis during the first few weeks of anti-tuberculosis treatment. It is more desirable over culture for its shorter time to results, almost zero rates of contamination, need for less expertise on the method, early rate of decline, lower running cost, and reproducibility. Its rapid and specific tuberculosis treatment monitoring competency benefits patients and healthcare providers to monitor changes of bacillary load among isolates with drug-susceptible or resistance to anti-tuberculosis regimens. Despite of the high installing cost of the tuberculosis molecular bacterial load assay method, molecular expertise, and a well-equipped laboratory, tuberculosis molecular bacterial load assay is a cost-effective method with comparison to culture in operational running. To achieve maximum utility in high tuberculosis burden settings, an intensive initial investment in nucleic acid extraction and polymerase chain reaction equipment, training in procedures, and streamlining laboratory supply procurement systems are crucial. More evidence is needed to demonstrate the potential large-scale and sustainable use of tuberculosis molecular bacterial load assay over culture in resource-constrained settings.
Keywords: Tuberculosis; culture; treatment monitoring; tuberculosis molecular bacterial load assay.
© The Author(s) 2021.
Conflict of interest statement
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
Burden of tuberculosis in intensive care units in Cape Town, South Africa, and assessment of the accuracy and effect on patient outcomes of the Xpert MTB/RIF test on tracheal aspirate samples for diagnosis of pulmonary tuberculosis: a prospective burden of disease study with a nested randomised controlled trial.Lancet Respir Med. 2015 Aug;3(8):621-30. doi: 10.1016/S2213-2600(15)00198-8. Epub 2015 Jul 22. Lancet Respir Med. 2015. PMID: 26208996 Clinical Trial.
-
Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment.Lancet Respir Med. 2013 Aug;1(6):462-70. doi: 10.1016/S2213-2600(13)70119-X. Epub 2013 Jul 1. Lancet Respir Med. 2013. PMID: 24429244 Clinical Trial.
-
Comparing rates of mycobacterial clearance in sputum smear-negative and smear-positive adults living with HIV.BMC Infect Dis. 2021 May 22;21(1):466. doi: 10.1186/s12879-021-06133-4. BMC Infect Dis. 2021. PMID: 34022850 Free PMC article.
-
The Xpert® MTB/RIF assay evaluation in South Korea, a country with an intermediate tuberculosis burden.Int J Tuberc Lung Dis. 2012 Nov;16(11):1471-6. doi: 10.5588/ijtld.11.0602. Epub 2012 Sep 12. Int J Tuberc Lung Dis. 2012. PMID: 22981162
-
Diagnostic accuracy of the new Xpert MTB/RIF Ultra for tuberculosis disease: A preliminary systematic review and meta-analysis.Int J Infect Dis. 2020 Jan;90:35-45. doi: 10.1016/j.ijid.2019.09.016. Epub 2019 Sep 20. Int J Infect Dis. 2020. PMID: 31546008
Cited by
-
Facilitators and barriers to implementing chest radiography in tuberculosis systematic screening of clinically high-risk groups in Ethiopia: A qualitative study.SAGE Open Med. 2024 Feb 19;12:20503121241233232. doi: 10.1177/20503121241233232. eCollection 2024. SAGE Open Med. 2024. PMID: 38379811 Free PMC article.
-
Diagnostic value of the Xpert MTB/RIF assay combined with endobronchial ultrasonography with a guide sheath for peripheral nodular pulmonary tuberculosis.BMC Infect Dis. 2024 Sep 20;24(1):1017. doi: 10.1186/s12879-024-09901-0. BMC Infect Dis. 2024. PMID: 39304805 Free PMC article.
-
Validity of InterVA model versus physician review of verbal autopsy for tracking tuberculosis-related mortality in Ethiopia.BMC Infect Dis. 2022 Mar 1;22(1):200. doi: 10.1186/s12879-022-07193-w. BMC Infect Dis. 2022. PMID: 35232392 Free PMC article.
-
New Insights into Biomarkers for Evaluating Therapy Efficacy in Pulmonary Tuberculosis: A Narrative Review.Infect Dis Ther. 2023 Dec;12(12):2665-2689. doi: 10.1007/s40121-023-00887-x. Epub 2023 Nov 8. Infect Dis Ther. 2023. PMID: 37938418 Free PMC article. Review.
-
The Role of G Protein-Coupled Receptors in the Regulation of Orthopaedic Diseases by Gut Microbiota.Nutrients. 2025 May 16;17(10):1702. doi: 10.3390/nu17101702. Nutrients. 2025. PMID: 40431441 Free PMC article. Review.
References
-
- Visca D, Centis R, Munoz-Torrico M, et al.. Post-tuberculosis sequelae: the need to look beyond treatment outcome. Int J Tuberc Lung Dis 2020; 24(8): 761–762. - PubMed
-
- Alemu A, Bitew ZW, Worku T. Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in Ethiopia: a systematic review and meta-analysis. Int J Infect Dis 2020; 98: 420–439. - PubMed
-
- Chedid C, Kokhreidze E, Tukvadze N, et al.. Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study. Int J Infect Dis 2020; 100: 199–206. - PubMed
-
- Manyazewal T, Marinucci F, Belay G, et al.. Implementation and evaluation of a blended learning course on tuberculosis for front-line health care professionals. Am J Clin Pathol 2017; 147(3): 285–291. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources